Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients
Authors not listed
University Hospital, Toulouse · 2018
Abstract
For this project, neflamapimod and placebo will be provided free of charge by the EIP company (www.eippharma.com). Neflamapimod is currently tested in 2 clinical trials in AD, one in Europe (The Netherlands) and one in the USA (clinical trials.gov/VX-745). The company commenced in May 2015 dosing in two phase 2a clinical studies in patients with Early AD: one in the Netherlands that is focused on PET amyloid imaging as the primary biomarker of drug effect, and one in the US (California) that is focused on Cerebrospinal fluid (CSF) evaluation to determine CSF drug concentrations and effects on inflammatory markers and disease biomarkers. Pharmacokinetic evaluation in these patients has demonstrated blood drug concentration levels in the predicted therapeutic range; and importantly, the data from the US study demonstrate that the drug achieves target drug concentrations in CSF, thus confirming the drug robustly enters the brain in humans.
The present project offers us a unique chance to test this promising drug in AD patients. The aim of the study is to focus on PET neuroinflammation imaging as the primary biomarker of this drug effect. The chosen biomarker for imaging neuroinflammation in patients is \[1 8F\]-DPA714.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Anonymous. (2018). Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients. <em>University Hospital, Toulouse</em>. https://clinicaltrials.gov/study/NCT03435861
Vancouver
Anonymous. Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients. University Hospital, Toulouse. 2018.
BibTeX
@misc{anon2018Effect,
title = {Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients},
author = {Anonymous},
journal = {University Hospital, Toulouse},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Pennsylvania 2014
Open access · US-GOV
[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia
Avid Radiopharmaceuticals 2017
Open access · US-GOV
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Assistance Publique - Hôpitaux de Paris 2021
Open access · US-GOV
Finding Retinal Biomarkers in Alzheimer's Disease
University Hospital, Toulouse 2013
Open access · US-GOV
Impact of a Therapeutic Educational Programme for Alzheimer's Disease Patients and Their Caregiver in Community Dwelling, on the AD Patient's Quality of Life
BMC Medicine 2020
Open access · CC-BY
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
Regulatory Mechanisms in Biosystems 2026
Open access · CC-BY